Literature DB >> 16849482

Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens.

Ian Giles1, Nancy Lambrianides, Nisha Pattni, David Faulkes, David Latchman, Pojen Chen, Silvia Pierangeli, David Isenberg, Anisur Rahman.   

Abstract

In the antiphospholipid syndrome (APS), antiphospholipid Abs (aPL) bind to anionic phospholipids (PL) and various associated proteins, especially beta(2)-glycoprotein I (beta2GPI) and prothrombin. In the present study, we show that altering specific Arg residues in the H chain of a human pathogenic beta2GPI-dependent aPL, IS4, has major effects on its ability to bind these clinically important Ags. We expressed whole human IgG in vitro by stable transfection of Chinese hamster ovary cells with expression plasmids containing different V(H) and V(L) sequences. V(H) sequences were derived from IS4 by altering the number of Arg residues in CDR3. V(L) sequences were those of IS4, B3 (anti-nucleosome Ab), and UK4 (beta2GPI-independent aPL). Binding of the expressed H/L chain combinations to a range of anionic, neutral, and zwitterionic PL, as well as prothrombin, beta2GPI, dsDNA, and chicken OVA, was determined by ELISA. Of four Arg residues in IS4VH CDR3 substituted to Ser, two at positions 100 and 100g, reduced binding to all Ags, while two at positions 96 and 97 reduced binding to beta2GPI but increased or decreased binding to different PL. Eleven of 14 H/L chain combinations displayed weak binding to OVA with Arg to Ser replacements of all four Arg residues enhancing binding to this Ag. Only one H/L chain combination bound neutral PL and none bound dsDNA; hence, these effects are particularly relevant to Ags important in antiphospholipid syndrome. We hypothesize that these four Arg residues have developed as a result of somatic mutations driven by an Ag containing both PL and beta2GPI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849482     DOI: 10.4049/jimmunol.177.3.1729

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Autoantibodies: Focus on anti-DNA antibodies.

Authors:  Nina Almqvist; Thomas H Winkler; Inga-Lill Mårtensson
Journal:  Self Nonself       Date:  2011-01-01

3.  Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Authors:  M Anthony Moody; Hua-Xin Liao; S Munir Alam; Richard M Scearce; M Kelly Plonk; Daniel M Kozink; Mark S Drinker; Ruijun Zhang; Shi-Mao Xia; Laura L Sutherland; Georgia D Tomaras; Ian P Giles; John C Kappes; Christina Ochsenbauer-Jambor; Tara G Edmonds; Melina Soares; Gustavo Barbero; Donald N Forthal; Gary Landucci; Connie Chang; Steven W King; Anita Kavlie; Thomas N Denny; Kwan-Ki Hwang; Pojen P Chen; Philip E Thorpe; David C Montefiori; Barton F Haynes
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

Review 4.  Antibodies to serine proteases in the antiphospholipid syndrome.

Authors:  Pojen P Chen; Ian Giles
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

5.  Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.

Authors:  Mei-Yun Zhang; Bang K Vu; Anil Choudhary; Hong Lu; Michael Humbert; Helena Ong; Munir Alam; Ruth M Ruprecht; Gerald Quinnan; Shibo Jiang; David C Montefiori; John R Mascola; Christopher C Broder; Barton F Haynes; Dimiter S Dimitrov
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

6.  Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways.

Authors:  Anastasia Lambrianides; Christopher J Carroll; Silvia S Pierangeli; Charis Pericleous; Ware Branch; Jurhee Rice; David S Latchman; Paul Townsend; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

7.  Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43.

Authors:  Yiannis Ioannou; Charis Pericleous; Ian Giles; David S Latchman; David A Isenberg; Anisur Rahman
Journal:  Arthritis Rheum       Date:  2007-01

8.  Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis.

Authors:  Anastasia Lambrianides; Tabitha Turner-Stokes; Charis Pericleous; Jasmine Ehsanullah; Eva Papadimitraki; Katie Poulton; Yiannis Ioannou; Andrew Lawrie; Ian Mackie; Pojen Chen; David Latchman; David Isenberg; Anisur Rahman; Ian Giles
Journal:  Arthritis Rheum       Date:  2011-11

9.  Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies.

Authors:  Charis Pericleous; Jennifer Miles; Diego Esposito; Acely Garza-Garcia; Paul C Driscoll; Anastasia Lambrianides; David Latchman; David Isenberg; Anisur Rahman; Yiannis Ioannou; Ian Giles
Journal:  Mol Immunol       Date:  2011-09-06       Impact factor: 4.407

10.  Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.

Authors:  Vera M Ripoll; Anastasia Lambrianides; Silvia S Pierangeli; Katie Poulton; Yiannis Ioannou; Wendy E Heywood; Kevin Mills; David S Latchman; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.